• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Pharma Expects Push-Back on Cancer Drug Costs

Article

After Steven Miller, CMO at Express Scripts, announced last week that his company would like to influence the oncology market, Pharma seems to have paid heed.

Payers are likely to put pressure on drugmakers to lower the cost of cancer medicines, particularly when alternative treatments are available, the head of Novartis' pharma division said on Tuesday.

"I think there will be increased pressure on oncology prices," David Epstein, head of Novartis' pharmaceutical division told an analyst call after the company reported fourth-quarter results.

The high price of new immuno-oncology drugs which are expected to be used in combination with other medicines would make it necessary to impose a limit on costs, he said.

"I fully expect whenever a payer has good therapeutic equivalents to be able to put pressure on," he said.

Link to the report on Reuters:

http://reut.rs/1Cg59Jj

Also read:

After Hep C, Express Scripts Aims to Influence Oncology Drug Costs

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.